Daiichi Sankyo Company Posts Lower Q1 Operating Profit Amid Currency Impact

TOKYO, Jul 31 (Pulse News Wire) – Daiichi Sankyo Company,limited (4568.T) reported lower operating profit for the fiscal first quarter ended June 30, 2026, compared to the same period last year. Operating profit was ¥851 million from ¥967 million, reflecting a decline of ¥116 million.

Revenue increased slightly to ¥23.4 billion from ¥22.8 billion due to favorable foreign exchange rates impacting sales revenue positively by ¥419 million. Core operating income also saw a decrease, dropping to ¥3.6 billion from ¥3.6 billion previously. Research and development expenses remained stable at ¥5 billion. Financial results were further impacted by a reduction in interest income and dividend receipts, leading to a drop in pre-tax income to ¥913 million from ¥1.054 billion.

In addition, the company noted adjustments related to restructuring activities and impairment losses, which affected overall profitability. Despite these challenges, the firm maintained a strong focus on key products such as ENHERTU and TRASTUZUMAB DERUXTECAN, contributing significantly to revenue growth across various regions. Looking ahead, management highlighted ongoing efforts to enhance operational efficiency and capitalize on emerging opportunities in oncology treatments. The company's strategic initiatives aim to drive sustainable growth and maintain competitive positioning within the pharmaceutical industry.